While researchers continue to work on a full cure for Alzheimer's disease, they're finding treatments that can help manage ...

In a phase 3 randomized clinical trial, donanemab slowed clinical disease progression in amyloid-positive, early symptomatic Alzheimer’s patients over 76 weeks. The drug is currently under regulatory ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

Why are researchers still fumbling in the quest to cure what is arguably one of the most important diseases confronting ...

A so-called 'miracle' Alzheimer's drug caused brain bleeds in more than a third of patients, a new study has revealed.

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...

Systematic fraud -- led by a "cabal of self-interested researchers, government accomplices, and corporate greed" in the words ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

Lecanemab and donanemab can help patients live independently Alzheimer's disease is a degenerative brain disorder affecting memory The two drugs can help patients stay independent by 10-13 months Two ...

Solano Garcia credits the drug donanemab, which she began taking as part of a clinical trial at the University of Southern California. The Food and Drug Administration approved the drug ...